The CTC offices are currently closed for refurbishment. Access to trial TMFs and patient records will be limited during this period. We will still be able to receive post during this time, but there may be a small delay in responding to this. Our fax lines may also be subject to disruption. Where possible, please direct all correspondence via email to trial-specific email addresses. We appreciate your patience and understanding.

Due to COVID-19 and current government guidance, UCL CTC staff continue to work remotely with limited access to the office. Please continue to email the trial specific mailbox with any urgent queries. For paper CRF trials, please continue to copy and scan CRFs to the trial inboxes (remove all patient identifiers except Trial Number and Initials) until further notice.

INCA trial presented at 25th European Hematology Association Conference
01 July 2020

The 25th EHA conference took place as a virtual exhibit last month (11th-21st June), with the CTC's INCA trial one of the studies receiving attention.

The conference consisted of a 10 day programme with live and on-demand sessions, including a session on the INCA trial presented by Dr Beth Phillips. 

INCA, which recruited its first patient in October 2013, was a phase II trial investigating whether the number of disease progressions and deaths in patients with diffuse large B-cell lymphoma (DLBCL) who were not fit to receive standard R-CHOP chemotherapy and were treated with IO-R-CVP (inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine and prednisolone) is lower than in patients treated with GEM-R-CVP (gemcitabine, rituximab, cyclophosphamide, vincristine and prednisolone). It also looked at patients' disease response, what side effects they experienced, and how treatment affected their quality of life.

It was concluded that there were no significant differences in the number of disease progressions and deaths in patients treated with IO-R-CVP vs GEM-R-CVP.  Higher risk patients (IPI score 3-5) had superior progression-free survival when treated with IO-R-CVP rather than GEM-R-CVP, possibly because GEM-R-CVP patients are able to receive fewer cycles of GEM.  Overall it was concluded that IO-R-CVP is an effective and deliverable treatment for patients with DLBCL who are not fit for standard chemotherapy, particularly in a group of high risk patients, where fewer cycles of GEM-R-CVP are able to be given.  

Further information on the presentation can be found on the EHA website.

For more details on the INCA trial, please see the CTC trial pages.

Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2021 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us